Sugi Predict

Sugi Predict / Compounds / SCHEMBL2914647

SCHEMBL2914647

SCHEMBL2914647

N[n+]1ccc(C(=O)N2CCC(c3cc[c]c(C4=CCCCC4)c3)CC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 8/20 0.43
▸ CYP3A4 P08684 3/20 0.38
▸ CYP2C19 P33261 4/20 0.37
▸ CYP2C9 P11712 2/20 0.37
▸ ALDH1A1 P00352 3/20 0.35
▸ CA12 O43570 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ CA7 P43166 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ CA14 Q9ULX7 1/20 0.35
▸ PARP10 Q53GL7 2/20 0.35
▸ CYP2D6 P10635 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ KIT P10721 4/20 0.34
▸ HSD11B1 P28845 1/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC2 Q92769 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2941304 0.89 CSF1R (0.44) CSF1RCYP3A4CYP2C19CYP2C9CA12
SCHEMBL18240996 0.81 CSF1R (0.54) CSF1RCYP3A4CYP2C19CYP2C9ALDH1A1
SCHEMBL4057863 0.77 CSF1R (0.49) CSF1RCYP3A4CYP2C19KITHDAC1
SCHEMBL18240980 0.77 CSF1R (0.41) CSF1RCYP3A4CYP2C19CYP2C9KIT
SCHEMBL18240960 0.73 CSF1R (0.45) CSF1RCYP3A4CYP2C19ALDH1A1KIT
SCHEMBL4983397 0.72 CSF1R (0.43) CSF1RCYP3A4CYP2C19CYP2C9KIT
SCHEMBL4977257 0.71 CSF1R (0.56) CSF1RCYP3A4CYP2C19CYP2C9KIT
SCHEMBL3010334 0.71 CSF1R (0.40) CSF1RCYP2C9KITHDAC1HDAC2
SCHEMBL3090316 0.69 ACMSD (0.33) HDAC1HDAC2
SCHEMBL4380557 0.69 CSF1R (0.49) CSF1RCYP3A4CYP2C19KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807077-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-11-23 — — EP claimed
US-7662837-B2 4-cyano-1H-imidazole-2-carboxylic acid {2-cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl}-amide; protein tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent JANSSEN PHARMACEUTICA N.V. (BE) 2010-02-16 — — US claimed
EP-1951234-A2 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-08-06 — — EP claimed
EP-1807077-A2 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 — — EP claimed
WO-2007048088-A2 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-04-26 — — WO claimed
US-20060189623-A1 Inhibitors of c-fms kinase ILLIG CARL R 2006-08-24 — — US claimed
US-20060148812-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-06 — — US claimed
WO-2006047277-A2 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 — — WO claimed
US-10806737-B2 Compounds and methods for the targeted degradation of fetal liver kinase polypeptides ARVINAS OPERATIONS, INC. (US) 2020-10-20 — — US disclosed
US-20180256586-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES ARVINAS OPERATIONS, INC. 2018-09-13 — — US disclosed
US-9526731-B2 Method of inhibiting C-KIT kinase JANSSEN PHARMACEUTICA NV (BE) 2016-12-27 — — US disclosed
EP-1807077-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-11-23 — — EP disclosed
US-20150094520-A1 METHOD OF INHIBITING C-KIT KINASE JANSSEN PHARMACEUTICA NV (BE) 2015-04-02 — — US disclosed
US-8933091-B2 Method of inhibiting C-KIT kinase JANSSEN PHARMACEUTICA NV (BE) 2015-01-13 — — US disclosed
EP-1807077-A2 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 — — EP disclosed
US-20070149572-A1 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-06-28 — — US disclosed
US-20060281788-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-14 — — US disclosed
US-20060189623-A1 Inhibitors of c-fms kinase ILLIG CARL R 2006-08-24 — — US disclosed
US-20060148812-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-06 — — US disclosed
WO-2006047277-A2 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189623-A1 Inhibitors of c-fms kinase MUSK, TYK2, FES CSF1R 34/4885CYP3A4 3871/4885CYP2C19 3150/4885
US-20180256586-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES MDM2, CRBN, FLT3 CSF1R 806/4885CYP3A4 4122/4885CYP2C19 4600/4885
US-20060281788-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR FLT3, MCL1, CSF1R CSF1R 3/4885CYP3A4 2047/4885CYP2C19 2318/4885
US-20060148812-A1 Inhibitors of c-fms kinase MUSK, TYK2, FES CSF1R 34/4885CYP3A4 3871/4885CYP2C19 3150/4885
US-10806737-B2 Compounds and methods for the targeted degradation of fetal liver kinase polypeptides MDM2, CRBN, FLT3 CSF1R 806/4885CYP3A4 4122/4885CYP2C19 4600/4885
US-20070149572-A1 METHOD OF INHIBITING FLT3 KINASE FLT3, PLK1, PHKG1 CSF1R 149/4885CYP3A4 3994/4885CYP2C19 4377/4885
US-20150094520-A1 METHOD OF INHIBITING C-KIT KINASE KIT, CHUK, MAP3K13 CSF1R 2973/4885CYP3A4 4130/4885CYP2C19 4271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.